Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome

Autoimmunity Reviews

Volumn 14, Issue 4, 2015, Pages 358-362

  Belizna, Cristina ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

Antiphospholipid syndrome; Hydroxycloroquine; Thrombosis

Indexed keywords

CARDIOLIPIN ANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID ANTIBODY;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; ERYTHROCYTE AGGREGATION; HUMAN; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE AGGREGATION; ANIMAL; DRUG EFFECTS; ERYTHROCYTE; LUPUS ERYTHEMATOSUS, SYSTEMIC; THROMBOCYTE; THROMBOSIS;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BLOOD PLATELETS; ERYTHROCYTES; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; THROMBOSIS;

EID: 84923106679     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.12.006     Document Type: Review

References (73)

1. Ruiz-Irastorza G., Egurbide M.V., Pijoan J.I., Garmendia M., Villar I., Martinez-Berriotxoa A., et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006, 15:577-583.
2. Ho K.T., Ahn C.W., Alarco G.S., Baethge B.A., Tan F.K., Roseman J., et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events 2005, 44:1303-1307. Rheumatology (Oxford).
3. Sisó A., Ramos-Casals M., Bové A., Brito-Zerón P., Soria N., Muñoz S., et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008, 17(4):281-288.
4. Kaiser R., Cleveland C.M., Criswell L.A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009, 68(2):238-241.
5. Tektonidou M.G., Laskari K., Panagiotakos D.B., Moutsopoulos H.M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009, 61:29-36.
6. Jung H., Bobba R., Su J., Shariati-Sarabi Z., Gladman D.D., Urowitz M., et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010, 62:863-868.
7. Edwards M.H., Pierangeli S., Liu X., Barker J.H., Anderson G., Harris E.N. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997, 96:4380-4384.
8. Broder A., Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol 2013, 40:30-33.
9. Reynaud Q., Lega J.C., Mismetti P., Chapelle C., Wahl D., Cathébras P., et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2014, 13:595-608.
10. Arnaud L., Mathian A., Ruffatti A., Erkan D., Tektonidou M., Cervera R., et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 2014, 13:281-291.
11. Comarmond C., Cacoub P. Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev 2013, 12:752-757.
12. Bazzan M., Vaccarino A., Stella S., Bertero M.T., Carignola R., Montaruli B., et al. Piedmont APS Consortium. Autoimmun Rev 2013, 12:826-831.
13. Pengo V., Banzato A., Denas G., Jose S.P., Bison E., Hoxha A., et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 2013, 12(8):832-834.
14. Bertolaccini M.L., Amengual O., Andreoli L., Atsumi T., Chighizola C.B., Forastiero R., et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Autoimmun Rev 2014, 13:917-930.
15. Erkan D., Aguiar C.L., Andrade D., Cohen H., Cuadrado M.J., Danowski A., et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014, 13:685-696.
16. Clark P., Casas E., Tugwell P., Medina C., Gheno C., Tenorio G., et al. ydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 1993, 119:1067-1071.
17. Fox R.I. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993, 23:82-91.
18. Wallace D.J., Linker-Israeli M., Metzger A.L., Stecher V.J. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 1993, 2(Suppl. 1):S13-S15.
19. Kyburz D., Brentano F., Gay S. Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2006, 2:458-459.
20. Lafyatis R., York M., Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors?. Arthritis Rheum 2006, 54:3068-3070.
21. Goldman F.D., Gilman A.L., Hollenback C., Kato R.M., Premack B.A., Rawlings D.J. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000, 95:3460-3466.
22. Genton E., Gent M., Hirsh J., Harker L.A. Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (third of three parts). N Engl J Med 1975, 293:1296-1300.
23. Jancinova V., Nosal R., Petrikova M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res 1994, 74:495-504.
24. Bertrand E., Cloitre B., Ticolat R., Bile R.K., Gautier C., Abiyou G.O., et al. Antiaggregation action of chloroquine. Med Trop 1990, 50:143-146.
25. Prowse C., Pepper D., Dawes J. Prevention of the platelet alpha-granule release reaction by membrane-active drugs. Thromb Res 1982, 25:219-227.
26. Nosál R., Jancinová V., Petríková M. Chloroquine inhibits stimulated platelets at the arachidonic acid pathway. Thromb Res 1995, 77:531-542.
27. Espinola R.G., Pierangeli S.S., Gharavi A.E., Harris E.N. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002, 87:518-522.
28. Cecchi E. Acta Med Scand 1962, 8:214-221.
29. Bird H.A., Harkness J., Wright V. Some rheological properties of blood during anti-rheumatoid therapy. Pharmatherapeutica 1981, 3:36-39.
30. Ernst E., Rose M., Lee R. Modification of transoperative changes in blood fluidity by hydroxychloroquine: a possible explanation for the drug's antithrombotic effect. Pharmatherapeutica 1984, 4:48-52.
31. Rand J.H., Wu X.X., Quinn A.S., Chen P.P., Hathcock J.J., Taatjes D.J. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008, 112:1687-1695.
32. Wallace D.J., Metzger A.L., Stecher V.J., Turnbull B.A., Kern P.A. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990, 89:322-326.
33. Petri M., Lakatta C., Magder L., Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994, 96:254-259.
34. Borba E.F., Bonfá E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001, 28:780-785.
35. Petri M. Hydroxychloroquine use in the Baltimore lupus cohort: effects on lipids, glucose and thrombosis. Lupus 1996, 5(Suppl. 1):S16-S22.
36. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991, 324:150-154. No authors listed.
37. Molad Y., Gorshtein A., Wysenbeek A.J., Guedj D., Majadla R., Weinberger A., et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Lupus 2002, 11(6):356-361.
38. Fessler B.J., Alarcón G.S., McGwin G., Roseman J., Bastian H.M., Friedman A.W., et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005, 52:1473-1480.
39. Alarcón G.S., McGwin G., Bertoli A.M., Fessler B.J., Calvo-Alén J., Bastian H.M., et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007, 66:1168-1172.
40. James J.A., Kim-Howard X.R., Bruner B.F., Jonsson M.K., McClain M.T., Arbuckle M.R., et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007, 16:401-409.
41. Shinjo S.K., Bonfá E., Wojdyla D., Borba E.F., Ramirez L.A., Scherbarth H.R., et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010, 62:855-862.
42. Loudon J.R. Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Am J Med 1988, 85:57-61.
43. Snook G.A., Chrisman O.D., Wilson T.C. Thromboembolism after surgical treatment of hip fractures. Clin Orthop Relat Res 1981, 155:21-24.
44. Johansson E., Forsberg K., Johnsson H. Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis 1981, 10:89-96.
45. Carter A.E., Eban R. Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulphate. Br Med J 1974, 3:94-95.
46. Pilcher D.B. Hydroxychloroquine sulfate in prevention of thromboembolic phenomena in surgical patients. Am Surg 1975, 41:761-766.
47. Hume M., Turner R.H., Kuriakose T.X., Surprenant J. Venous thrombosis after total hip replacement. Combined monitoring as a guide for prophylaxis and treatment. J Bone Joint Surg Am 1976, 58:933-939.
48. Johnson R., Green J.R., Charnley J. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement. Clin Orthop Relat Res 1977, 127:123-132.
49. Johnson R., Charnley J. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin Orthop Relat Res 1979, 144:174-177.
50. Wu T.K., Tsapogas M.J., Jordan F.R. Prophylaxis of deep venous thrombosis by hydroxychloroquine sulfate and heparin. Surg Gynecol Obstet 1977, 145:714-718.
51. Cooke E.D., Dawson M.H., Ibbotson R.M., Bowcock S.A., Ainsworth M.E., Pilcher M.F. Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. J Bone Joint Surg Am 1977, 59:496-500.
52. Wallace D.J. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?. Arthritis Rheum 1987, 30:1435-1436.
53. Barbhaiya M., Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?. Curr Rheumatol Rep 2011, 13:59-69.
54. Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011, 13:77-80.
55. Pierangeli S.S., Erkan D. Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?. Lupus 2010, 19:475-485.
56. Ruiz-Irastorza G., Crowther M., Branch W., Khamashta M.A. Antiphospholipid syndrome. Lancet 2010, 376:1498-1509.
57. Rand J.H., Wu X.X., Quinn A.S., Taatjes D.J. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 2010, 19:460-469.
58. Erkan D., Lockshin M.D. New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol 2009, 5:160-170.
59. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69:20-28.
60. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996, 25:191-193.
61. Erkan D., Yazici Y., Peterson M.G., Sammaritano L., Lockshin M.D. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002, 41:924-929.
62. Schmidt-Tanguy A., Voswinkel J., Henrion D., Subra J.F., Loufrani L., Rohmer V., et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost 2013, 11:1927-1929.
63. Mok M.Y., Chan E.Y., Fong D.Y., Leung K.F., Wong W.S., Lau C.S. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol 2005, 32:622-628.
64. Myones B.L., McCurdy D. The antiphospholipid syndrome: immunologic and clinical aspects. J Rheumatol 2000, 27(Suppl. 58):20-28.
65. Guyatt G., Gutterman D., Baumann M.H., Addrizzo-Harris Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 2006, 129:174-181.
66. Metjian A., Lim W. ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?. Hematology 2009, 247-9.
67. Marmor M.F., Kellner U., Lai T.Y., Lyons J.S., Mieler W.F. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011, 118:415-422. American Academy of Ophthalmology.
68. Rand J.H., Wu X.X., Quinn A.S., Chen P.P., McCrae K.R., Bovill E.G., et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 2003, 163:1193-1200.
69. Rand J.H., Wu X.X., Quinn A.S., Ashton A.W., Chen P.P., Hathcock J.J., et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010, 115:2292-2299.
70. Kavanaugh A., Adams-Huet B., Jain R., Denke M., McFarlin J. Hydroxychloroquine Effects on Lipoprotein Profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 1997, 3(1):3-8.
71. Pierangeli S.S., Harris E.N. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus 1994, 3:247-251.
72. Khamashta M.A., Harris E.N., Gharavi A.E., Derue G., Gil A., Vázquez J.J., et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988, 47:849-854.
73. Belizna C., Lartigue A., Favre J., Gilbert D., Tron F., Lévesque H., et al. Antiphospholipid antibodies induce vascular functional changes in mice: a mechanism of vascular lesions in antiphospholipid syndrome?. Lupus 2008, 17:185-194.